Inclusion dynamics in PC12 is comparable between amphetamines and MPTP

Annals of the New York Academy of Sciences

Volumn 1074, Issue , 2006, Pages 315-319

  Gesi, Marco ^a   Lazzeri, Gloria ^a   Ferrucci, Michela ^a   Pellegrini, Antonio ^a   Lenzi, Paola ^a   Ruggieri, Stefano ^b   Fornai, Francesco ^a,b   Paparelli, Antonio ^a  

^a UNIVERSITY OF PISA   (Italy)

^b IRCCS NEUROMED   (Italy)

Author keywords

1,4 methylphenylpyridinium; Amphetamine derivatives; Catecholamine cells; Morphological analysis

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE DERIVATIVE; CATECHOLAMINE; METHAMPHETAMINE; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; CELL INCLUSION; CELL STRAIN; CELL STRUCTURE; CONFERENCE PAPER; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PHEOCHROMOCYTOMA CELL; RAT;

EID: 33749570341     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1369.028     Document Type: Conference Paper

References (15)

1. LEWY, F.H. 1912. In Handbuch der Neurologie. M. LEWANDOWSKY Ed.: 920-933. Springer. Berlin.
2. GREENFIELD, I.G. & F.D. BOSANQUET. 1953. The brain-stem lesions in Parkinsonism. J. Neurol. Neurosurg. Psychiatry 16: 213-226.
3. OHAMA, E. & F. IKUTA. 1976. Parkinson's disease: distribution of Lewy bodies and monoamine neuron system. Acta Neuropathol. (Berl.) 34: 311-319.
4. ZWEIG, R.M. et al. 1989. Linkage to the Huntington's disease locus in a family with unusual clinical and pathological features. Ann. Neurol. 26: 78-84.
5. CIECHANOVER, A. 1998. The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J. 17: 7151-7160.
6. MCNAUGHT, K.S. & P. JENNER. 2001. Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci. Lett. 297: 191-194.
7. FORNAI, F. et al. 2003. Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition. J. Neurosci. 23: 8955-8966.
8. FORNAI, F. et al. 2004. Methamphetamine produces neuronal inclusions in the nigrostriatal system and in PC12 cells. J. Neurochem. 88: 114-123.
9. LANGSTON, J.W. & P. BALLARD. 1984. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease. Can. J. Neurol. Sci. 11(1 Suppl): 160-165.
10. SONSALLA, P.K. et al. 1992. Characteristics of dopaminergic neurotoxicity produced by MPTP and methamphetamine. Ann. N. Y. Acad. Sci. 648: 229-238.
11. + and paraquat on mitochondrial potential and oxidative stress. Life Sci. 44: 1277-1284.
12. CUBELLS, J.F. et al. 1994. Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J. Neurosci. 14:2260-2271.
13. LARSEN, K.E. et al. 2002. Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis. J. Neurosci. 22:8951-8960.
14. FORNAI, F. et al. 2005. Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc. Natl. Acad. Sci. USA 102: 3413-3418.
15. HOGLINGER, G.U. et al. 2003. Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease. J. Neurochem. 86: 1297-1307.